Detail
| LncRNA Name | TUG1 |
| Synonyms | TUG1, LINC00080, NCRNA00080, TI-227H, FLJ20618 |
| Region | GRCh38_22:30969245-30979395 Sequence |
| Ensembl | ENSG00000253352 |
| RefSeq | NR_002323 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✘ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Flow cytometry assay, Western Blot, Luciferase reporter assay, etc. |
| Sample | RWPE1 and PCa cell lines (DU145, PC-3, LNCaP, 22Rv1). patients in tumor and adjacent normal tissue. |
| Expression Pattern | up-regulated |
| Function Description | In conclusion, our study suggests that lncRNA TUG1 acts as a functional oncogene in PCa development. TUG1 could negatively regulate the expression of miR-26a in PCa cells. The bioinformatics prediction revealed putative miR-26a binding sites within TUG1 transcripts. |
| Pubmed ID | 29967294 |
| Year | 2018 |
| Title | TUG1 promotes prostate cancer progression by acting as a ceRNA of miR-26a. |
| External Links |
| Links for TUG1 | GenBank HGNC lncrnadb Noncode |
| Links for prostate cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.